[go: up one dir, main page]

SI1019395T1 - Farnesyl transferase inhibiting 2-quinolone derivatives - Google Patents

Farnesyl transferase inhibiting 2-quinolone derivatives

Info

Publication number
SI1019395T1
SI1019395T1 SI9630453T SI9630453T SI1019395T1 SI 1019395 T1 SI1019395 T1 SI 1019395T1 SI 9630453 T SI9630453 T SI 9630453T SI 9630453 T SI9630453 T SI 9630453T SI 1019395 T1 SI1019395 T1 SI 1019395T1
Authority
SI
Slovenia
Prior art keywords
farnesyl transferase
quinolone derivatives
transferase inhibiting
inhibiting
quinolone
Prior art date
Application number
SI9630453T
Other languages
English (en)
Slovenian (sl)
Inventor
David William End
Marc Gaston c/o Janssen Cilag VENET
Patrick Rene c/o Janssen Cilag ANGIBAUD
Gerard Charles c/o Janssen Cilag SANZ
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of SI1019395T1 publication Critical patent/SI1019395T1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI9630453T 1995-10-31 1996-10-25 Farnesyl transferase inhibiting 2-quinolone derivatives SI1019395T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP95202945 1995-10-31
PCT/EP1996/004661 WO1997016443A1 (en) 1995-10-31 1996-10-25 Farnesyl transferase inhibiting 2-quinolone derivatives
EP96937249A EP1019395B1 (en) 1995-10-31 1996-10-25 Farnesyl transferase inhibiting 2-quinolone derivatives

Publications (1)

Publication Number Publication Date
SI1019395T1 true SI1019395T1 (en) 2002-06-30

Family

ID=8220785

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9630453T SI1019395T1 (en) 1995-10-31 1996-10-25 Farnesyl transferase inhibiting 2-quinolone derivatives

Country Status (28)

Country Link
US (1) US5968952A (xx)
EP (2) EP1019395B1 (xx)
JP (1) JP4257869B2 (xx)
KR (1) KR100417620B1 (xx)
CN (1) CN1101391C (xx)
AR (1) AR004699A1 (xx)
AT (2) ATE212627T1 (xx)
AU (1) AU712435B2 (xx)
CA (1) CA2231143C (xx)
CY (1) CY2287B1 (xx)
CZ (1) CZ290954B6 (xx)
DE (2) DE69632751T2 (xx)
DK (1) DK1019395T3 (xx)
EA (1) EA000719B1 (xx)
ES (2) ES2233557T3 (xx)
HU (1) HU224032B1 (xx)
IL (1) IL123567A (xx)
MY (1) MY116577A (xx)
NO (1) NO314037B1 (xx)
NZ (1) NZ321576A (xx)
PL (1) PL184168B1 (xx)
PT (1) PT1019395E (xx)
SI (1) SI1019395T1 (xx)
SK (1) SK282642B6 (xx)
TR (1) TR199800720T2 (xx)
TW (1) TW349948B (xx)
WO (1) WO1997016443A1 (xx)
ZA (1) ZA969087B (xx)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE222104T1 (de) * 1997-06-02 2002-08-15 Janssen Pharmaceutica Nv (imidazol-5-yl)methyl-2-quinolinone derivativen als inhibitoren von proliferation der glatten muskelzellen
US6565831B1 (en) 1999-02-24 2003-05-20 Oncolytics Biotech Inc. Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
US6136307A (en) * 1997-08-13 2000-10-24 Oncolytics Biotech Inc. Reovirus for the treatment of cellular proliferative disorders
EP1037880B1 (en) 1997-12-11 2004-06-30 Janssen Pharmaceutica N.V. Retinoic acid mimetic anilides
US6420555B1 (en) 1998-06-16 2002-07-16 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Imidazolyl derivatives
ES2216535T3 (es) * 1998-06-16 2004-10-16 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Derivados de imidazolilo.
PT1094839E (pt) * 1998-07-06 2003-09-30 Janssen Pharmaceutica Nv Inibidores da proteina farnesil transferase com propriedades de radiossensibilizacao (in vivo)
HRP20000904A2 (en) 1998-07-06 2001-12-31 Janssen Pharmaceutica Nv Farnesyl protein transferase inhibitors for treating arthropathies
FR2780892B1 (fr) * 1998-07-08 2001-08-17 Sod Conseils Rech Applic Utilisation d'inhibiteurs de prenyltransferases pour preparer un medicament destine a traiter les pathologies qui resultent de la fixation membranaire de la proteine g heterotrimerique
AU4925199A (en) 1998-08-27 2000-03-21 Pfizer Products Inc. Quinolin-2-one derivatives useful as anticancer agents
ES2259237T3 (es) * 1998-08-27 2006-09-16 Pfizer Products Inc. Derivados de quinolin-2-ona alquinilsustituidos utiles como agentes anticancerosos.
WO2000034437A2 (en) 1998-12-08 2000-06-15 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6316436B1 (en) 1998-12-08 2001-11-13 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
EA004542B1 (ru) 1998-12-23 2004-06-24 Янссен Фармацевтика Н.В. 1, 2-аннелированные производные хинолина
AU2124800A (en) 1999-02-11 2000-08-29 Pfizer Products Inc. Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents
US6143766A (en) * 1999-04-16 2000-11-07 Warner-Lambert Company Benzopyranone and quinolone inhibitors of ras farnesyl transferase
EP1420015A1 (en) * 1999-06-11 2004-05-19 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Imidazolyl derivatives
ES2212971T3 (es) * 1999-11-30 2004-08-16 Pfizer Products Inc. Derivados de quinolina utiles para la inhibicion de la farnesil protein transferasa.
HN2000000266A (es) * 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
EP1267848B1 (en) 2000-02-24 2007-10-17 Janssen Pharmaceutica N.V. Dosing regimen comprising a farnesyl protein transferase inhibitor for the treatment of cancer
EP1261356A2 (en) * 2000-02-29 2002-12-04 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with platinum compounds
EP1263437A2 (en) * 2000-02-29 2002-12-11 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with vinca alkaloids
WO2001064246A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with an her2 antibody
WO2001064217A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents
CA2397253A1 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
JP2003525245A (ja) * 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤
EP1261341A2 (en) * 2000-02-29 2002-12-04 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with camptothecin compounds
EP1261374A2 (en) * 2000-02-29 2002-12-04 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
JP2003525235A (ja) * 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗腫瘍ヌクレオシド誘導体とのファルネシルタンパク質トランスフェラーゼ阻害剤の組み合わせ剤
CA2397425A1 (en) * 2000-02-29 2001-09-07 Ivan David Horak Farnesyl protein transferase inhibitor combinations with taxane compounds
JP2003525238A (ja) * 2000-02-29 2003-08-26 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗腫瘍性ポドフィロトキシン誘導体とのファルネシルタンパク質トランスフェラーゼ阻害剤組み合わせ剤
US6844357B2 (en) * 2000-05-01 2005-01-18 Pfizer Inc. Substituted quinolin-2-one derivatives useful as antiproliferative agents
JO2361B1 (en) * 2000-06-22 2006-12-12 جانسين فارماسيوتيكا ان. في Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
WO2002024682A1 (en) * 2000-09-25 2002-03-28 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors
JP4974437B2 (ja) * 2000-09-25 2012-07-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する６−［（置換フェニル）メチル］−キノリンおよびキナゾリン誘導体
EP1322644A1 (en) * 2000-09-25 2003-07-02 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
ATE434615T1 (de) * 2000-11-21 2009-07-15 Janssen Pharmaceutica Nv Farnesyltransferase hemmende benzoheterocyclische derivate
ES2261523T3 (es) * 2000-11-28 2006-11-16 Janssen Pharmaceutica N.V. Inhibidores de farnesil proteina transferasa para el tratamiento de enfermedad intestinal inflamatoria.
EP1395577A1 (en) * 2000-12-19 2004-03-10 Pfizer Products Inc. Crystal forms of 6- (4-chloro-phenyl)-hydroxy-(-3-methyl-3h-imidaol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1h-quinolin-2-one, 2,3-dihydroxybutanedioate salts and method of production
DE60119383T2 (de) * 2000-12-27 2007-04-19 Janssen Pharmaceutica N.V. Farnesyltransferasehemmende 4-heterocyclylchinolin- und chinazolinderivate
WO2002051835A1 (en) * 2000-12-27 2002-07-04 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives
DE60230017D1 (de) * 2001-02-15 2009-01-08 Janssen Pharmaceutica Nv Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen
WO2002072574A1 (en) 2001-03-12 2002-09-19 Janssen Pharmaceutica N.V. Process for the preparation of imidazole compounds
US6740757B2 (en) 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
CA2469275C (en) 2001-12-19 2011-09-06 Janssen Pharmaceutica N.V. 1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors
ATE364384T1 (de) * 2002-03-22 2007-07-15 Janssen Pharmaceutica Nv Benzylimidazolyl substituierte 2-chinolon und chinazolinon derivate zur verwendung als farnesyl transferase inhibitoren
ES2271574T3 (es) 2002-04-15 2007-04-16 Janssen Pharmaceutica N.V. Derivados triciclicos de quinazolina inhibidores de la farnesiltransferasa, sustituidos con imidazoles o triazoles enlazados al carbono.
FR2841243B1 (fr) * 2002-06-19 2004-08-20 Servier Lab Nouveaux derives de 3-(4-oxo-4h-chromen-2yl)-(1h)-quinolein- 4-ones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20030125268A1 (en) * 2002-08-28 2003-07-03 Rybak Mary Ellen Margaret Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives
FR2860235A1 (fr) * 2003-09-29 2005-04-01 Yang Ji Chemical Company Ltd Utilisation d'un compose de formule (i) inhibiteur de l'aromatase a des fins therapeutiques et composes de formule (i) en tant que tels
WO2005089518A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Uch-l1 expression and cancer therapy
NZ588431A (en) * 2004-09-17 2012-02-24 Whitehead Biomedical Inst Using Benzimidazole or Indole compounds with a 1,2-diazole group to Inhibit Alpha-Synuclein Toxicity
WO2006052718A2 (en) 2004-11-05 2006-05-18 Janssen Pharmaceutica N.V. Farnesyltransferase inhibitors for treating sepsis
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
US20060281755A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
US20060281769A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators
US20060281788A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
US20070004660A1 (en) * 2005-06-10 2007-01-04 Baumann Christian A Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines
US7833339B2 (en) 2006-04-18 2010-11-16 Franklin Industrial Minerals Mineral filler composition
EP2545919A1 (en) 2005-12-23 2013-01-16 Link Medicine Corporation Treatment of synucleinopathies
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
WO2007124316A1 (en) 2006-04-20 2007-11-01 Janssen Pharmaceutica N.V. Heterocyclic compounds as inhibitors of c-fms kinase
NZ572072A (en) 2006-04-20 2011-09-30 Janssen Pharmaceutica Nv Inhibitors of c-fms kinase
DE102007015709B4 (de) 2007-01-25 2009-09-03 Webasto Ag Fahrzeugdach
KR20100025553A (ko) 2007-06-05 2010-03-09 쉐링 코포레이션 암 치료용 ｅｒｋ 억제제로서의 폴리사이클릭 인다졸 유도체 및 이의 용도
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
US7932036B1 (en) 2008-03-12 2011-04-26 Veridex, Llc Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
US8232402B2 (en) 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
WO2009117484A2 (en) 2008-03-18 2009-09-24 University Of South Florida Small molecule e2f inhibitor
CA2743717A1 (en) 2008-11-13 2010-05-20 Link Medicine Corporation Azaquinolinone derivatives and uses thereof
AU2010300925A1 (en) 2009-09-30 2012-03-29 Merck Sharp & Dohme Corp. Novel compounds that are ERK inhibitors
AU2011237642B2 (en) 2010-04-06 2014-05-01 Brigham Young University Antimetastatic compounds
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
ES2705719T3 (es) 2010-07-28 2019-03-26 Janssen Diagnostics Llc Métodos de determinación de la respuesta de la leucemia mieloide aguda al tratamiento con inhibidores de la farnesiltransferasa
EP2616453A4 (en) * 2010-08-24 2014-07-02 Univ Brigham Young ANTI Metastases CONNECTIONS
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
WO2013052465A1 (en) 2011-10-02 2013-04-11 Trustees Of Boston University [1,3]dioxolo[4,5-g]quinoline-6(5h)thione and [1,3]dioxolo[4,5-g][1,2,4]triazolo[1,5-a]quinoline derivatives as inhibitors of the late sv40 factor (lsf) for use in treating cancer
JOP20180012A1 (ar) 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
ES2608628T3 (es) 2012-08-07 2017-04-12 Janssen Pharmaceutica Nv Procedimiento para la preparacion de derivados de ester heterociclicos
EP3103455A4 (en) 2014-02-07 2017-10-04 National University Corporation Tokyo Medical and Dental University Myogenesis accelerator, amyotrophy suppressor, medicinal composition, and taz activator
HUE057306T2 (hu) 2015-08-17 2022-04-28 Kura Oncology Inc Módszerek rákos páciensek kezelésére farneziltranszferáz inhibitorokkal
EP3133065A1 (en) 2015-08-21 2017-02-22 Merck Patent GmbH Compounds for optically active devices
EP3133066A1 (en) * 2015-08-21 2017-02-22 Merck Patent GmbH Hydrophilic compounds for optically active devices
WO2017034877A1 (en) * 2015-08-27 2017-03-02 Janssen Pharmaceutica Nv Chemically modified quinoline and quinolone derivatives useful as cb-1 inverse agonists
TW201818965A (zh) 2016-11-03 2018-06-01 美商庫拉腫瘤技術股份有限公司 以法呢基轉移酶（ｆａｒｎｅｓｙｌ ｔｒａｎｓｆｅｒａｓｅ）抑制劑治療癌症病患之方法
EP3363786A1 (en) 2017-02-15 2018-08-22 Merck Patent GmbH Compounds for optically active devices
EP3363793A1 (en) 2017-02-15 2018-08-22 Merck Patent GmbH Hydrophobic compounds for optically active devices
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
US20220143006A1 (en) 2019-03-15 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3900501A (en) * 1970-12-23 1975-08-19 Hoffmann La Roche Benzophenone intermediates for 7-lower alkanoyl benzodiazepines
IL65709A (en) * 1981-05-18 1986-01-31 Chevron Res Electroactive polymers
JPS63275548A (ja) * 1987-05-02 1988-11-14 Res Inst For Prod Dev ｏ−アミノベンゾイル化合物の製造方法
CA2002859C (en) * 1988-11-29 1998-12-29 Jean P. F. Van Wauwe Method of treating epithelial disorders
CA2002864C (en) * 1988-11-29 1999-11-16 Eddy J. E. Freyne (1h-azol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives
EP0574992A1 (en) * 1992-06-17 1993-12-22 Glaxo Group Limited 5-(1,2,4-Triazol-1-ylmethyl)-3H-isobenzofuran-1-one derivatives, their preparation and use as aromatase inhibitors
ES2134971T3 (es) * 1994-04-15 1999-10-16 Takeda Chemical Industries Ltd Derivado de acido octahidro-2-naftaleno-carboxilico, su produccion y uso.

Also Published As

Publication number Publication date
CY2287B1 (en) 2003-07-04
SK55698A3 (en) 1999-02-11
DE69618999D1 (de) 2002-03-14
HUP9802424A3 (en) 2003-02-28
EP1106610B1 (en) 2004-06-16
NO314037B1 (no) 2003-01-20
CZ127298A3 (cs) 1998-12-16
EP1019395A1 (en) 2000-07-19
PL184168B1 (pl) 2002-09-30
NO980928D0 (no) 1998-03-04
DE69632751T2 (de) 2005-08-04
NO980928L (no) 1998-04-29
HK1036064A1 (en) 2001-12-21
JP4257869B2 (ja) 2009-04-22
SK282642B6 (sk) 2002-10-08
CA2231143A1 (en) 1997-05-09
CA2231143C (en) 2005-06-21
EP1106610A1 (en) 2001-06-13
AU712435B2 (en) 1999-11-04
DE69632751D1 (de) 2004-07-22
HUP9802424A2 (hu) 1999-10-28
CN1101391C (zh) 2003-02-12
KR100417620B1 (ko) 2004-05-27
KR19990063639A (ko) 1999-07-26
PL328230A1 (en) 1999-01-18
ES2171736T3 (es) 2002-09-16
ATE269322T1 (de) 2004-07-15
ZA969087B (en) 1998-04-29
AU7493396A (en) 1997-05-22
EA199800395A1 (ru) 1998-10-29
CZ290954B6 (cs) 2002-11-13
TW349948B (en) 1999-01-11
NZ321576A (en) 1999-05-28
US5968952A (en) 1999-10-19
WO1997016443A1 (en) 1997-05-09
ES2233557T3 (es) 2005-06-16
DK1019395T3 (da) 2002-05-06
ATE212627T1 (de) 2002-02-15
HU224032B1 (hu) 2005-05-30
MX9802067A (es) 1998-08-30
HK1027576A1 (en) 2001-01-19
AR004699A1 (es) 1999-03-10
EA000719B1 (ru) 2000-02-28
DE69618999T2 (de) 2002-09-26
MY116577A (en) 2004-02-28
EP1019395B1 (en) 2002-01-30
IL123567A (en) 2002-11-10
TR199800720T2 (xx) 1998-09-21
JPH11514635A (ja) 1999-12-14
CN1200732A (zh) 1998-12-02
IL123567A0 (en) 1998-10-30
PT1019395E (pt) 2002-07-31

Similar Documents

Publication Publication Date Title
HUP9802424A3 (en) Farnesyl transferase inhibiting 2-quinolone derivatives
IL123155A0 (en) 4-mercaptopyrrolidine derivatives as farnesyl transferase inhibitors
AP9801257A0 (en) Farnesyl protein transferase inhibiting (imidazol-5-YL) methyl-2-quinoline derivatives
EP0833633A4 (en) INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
IL122812A0 (en) 4,9-ethano-benzo (F) isoindole derivatives as farnesyl transferase inhibitors
EP0817629A4 (en) FARNESYL PROTEIN TRANSFERASE INHIBITORS
HU9602516D0 (en) Isoprenyl transferase inhibitors
PL326967A1 (en) Quinoline derivatives
GB2306473A8 (en) Glucoxide derivatives
GB9505864D0 (en) Hydrate Inhibition
GB9506174D0 (en) Inhibitors of farnesyl-protein transferase
IL130453A0 (en) Farnesyl transferase inhibitors
GB9524976D0 (en) Subsea clamp
ZA958225B (en) Inhibitors of farnesyl-protein transferase
IL155594A0 (en) Farnesyl transferase inhibitors
ZA971254B (en) Farnesyl transferase inhibitors
SI0948483T1 (en) Farnesyl transferase inhibitors
IL141626A0 (en) Farnesyl transferase inhibitors
GB2307940B (en) Subsea clamp
ZA962433B (en) Inhibitors of farnesyl-protein transferase
GB9610174D0 (en) Prenyl transferase inhibitors
GB9519595D0 (en) Inetellectual sovereignty
ZA958162B (en) Inhibitors of farnesyl-protein transferase
GB9509472D0 (en) Diazinone derivatives